Trial Profile
CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Recombinant Human Leptin (METRELEPTIN) in Various Forms of Partial Lipodystrophy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Metreleptin (Primary)
- Indications Lipodystrophy
- Focus Therapeutic Use
- 23 Mar 2021 Results presented at the 103rd Annual Meeting of the Endocrine Society
- 30 Oct 2020 Status changed from active, no longer recruiting to completed.
- 22 Oct 2019 Planned End Date changed from 1 Feb 2025 to 1 Jun 2020.